下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Immunohistochemical Expression of Laminin 332 in Triple-Negative Breast Carcinoma: A Cross-Sectional Study.
所有TNBC患者laminin 322均为阳性,但仅与淋巴血管侵犯存在统计学显著关联。因此,TNBC表现出侵袭性行为,并与不良的临床病理结局相关。
乳腺癌(BC)是女性最常见的恶性肿瘤,也是女性死亡的主要原因。三阴性乳腺癌(TNBC)基于免疫组化(IHC)是一种异质性疾病,表现为雌激素受体(ER)阴性、孕激素受体(PR)阴性和人表皮生长因子(HER2)阴性。TNBC具有独特的分子特征,侵袭性更强,缺乏靶向治疗,且预后较其他类型乳腺癌更差。层粘连蛋白是一种糖蛋白,在癌症进展中发挥多种作用,包括细胞增殖、侵袭、转移和上皮-间质转化。目的与目标:本研究旨在评估TNBC中层粘连蛋白332的免疫组化表达,并研究层粘连蛋白332表达与TNBC临床病理参数之间的关联。
2019年1月至2024年9月期间,从RL Jalappa医院和研究机构外科送至位于卡纳塔克邦Tamaka的Sri Devaraj Urs医学院附属病理科的所有TNBC病例均被纳入本研究。前瞻性和回顾性病例均被纳入。数据和石蜡块从病理科档案中调取。研究了TNBC病例的组织病理学参数,并进行了laminin 332 IHC检测。评估了laminin 332的IHC表达与组织病理学参数的关联。
在50例TNBC病例中,26例(56%)为50岁以上的老年患者。较高比例的病例,即23例(46%),为3级肿瘤;46例(92%)为浸润性导管癌(IDC);39例(78%)存在淋巴血管侵犯(LVI);46例(92%)无神经周围侵犯(PNI);22例(44%)具有高级别TIL(肿瘤浸润淋巴细胞)(TILS)。所有TNBC病例均表现为laminin 332 IHC评分5(64%)或laminin 332 IHC评分6(36%)阳性。laminin 332 IHC评分5(71.8%)与LVI的存在相关,而laminin IHC评分6(p值0.041)和7(63.6%)与LVI的缺失相关,其与p值0.041具有统计学显著相关性。
BACKGROUND: Breast carcinoma (BC) is the most common malignancy among women and is the leading cause of mortality among females. Triple-negative breast carcinoma (TNBC) is a diverse disease based on immunohistochemistry (IHC) and is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor (HER2) negative. TNBC has a distinct molecular profile, is more aggressive, lacks targeted therapies, and has a worse prognosis than other types of breast cancer. Laminin is a glycoprotein that plays several roles in cancer progression, including cell proliferation, invasion, metastasis, and epithelial-mesenchymal transition. AIM AND OBJECTIVES: This study aimed to evaluate the immunohistochemical expression of laminin 332 in TNBCs and to study the association of laminin 332 expression with clinicopathological parameters of TNBCs. MATERIALS AND METHODS: All the cases of TNBC received from the Department of Surgery at RL Jalappa Hospital and Research Institute to the Department of Pathology attached to Sri Devaraj Urs Medical College, Tamaka, Karnataka, from January 2019 to September 2024 were considered for the study. Both prospective and retrospective cases were considered. The data and paraffin blocks were retrieved from the archives of the Department of Pathology. Histopathological parameters of TNBC cases were studied, and laminin 332 IHC was performed. The association of IHC expression of laminin 332 and histopathological parameters was evaluated. RESULTS: Among 50 TNBC cases, 26 (56%) were elderly patients above 50 years of age. A higher proportion of cases, i.e., 23 (46%), were grade 3 tumors; 46 (92%) cases had infiltrating ductal carcinomas (IDC); 39 (78%) had lymphovascular invasion (LVI); 46 (92%) were without perineural invasion (PNI); and 22 (44%) had high-grade tumor-infiltrating lymphocytes (TILS). All the TNBC cases exhibited positivity for either a laminin 332 IHC score of 5 (64%) or a laminin 332 IHC score of 6 (36%). Laminin 332 IHC score of 5 (71.8%) was associated with the presence of LVI, and laminin IHC scores of 6 ( p-value 0.041) and 7 (63.6%) were associated with the absence of LVI, which has a statistically significant association with p-value 0.041. CONCLUSIONS: All the TNBC patients were positive for laminin 322, but there was a statistically significant association only with lymphovascular invasion. TNBC, hence, exhibits aggressive behavior and is associated with unfavorable clinicopathological outcomes.
MEMBER ACCOUNT
登录成功会直接打开下一页。